Clinical trial
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis…
NCT00050232 · Avanir Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00050232 |
|---|---|
| Title | Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients |
| Lead sponsor | Avanir Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | AVP-923 |
| Enrollment | 96 |
| Start date | Dec 1, 2002 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Dec 3, 2002 |
| Last update posted | Jul 14, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: